PeptiDream (4587) Panoramica del titolo
PeptiDream Inc. è un'azienda biofarmaceutica che si occupa della scoperta e dello sviluppo di peptidi vincolati, piccole molecole e farmaci peptidici coniugati. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 0/6 |
4587 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di PeptiDream Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | JP¥1,167.00 |
| Massimo di 52 settimane | JP¥2,029.00 |
| Minimo di 52 settimane | JP¥1,120.50 |
| Beta | 0.18 |
| Variazione di 1 mese | -6.64% |
| Variazione a 3 mesi | -25.38% |
| Variazione di 1 anno | -42.18% |
| Variazione a 3 anni | -36.02% |
| Variazione a 5 anni | -75.53% |
| Variazione dall'IPO | 62.37% |
Notizie e aggiornamenti recenti
4587: Out Licensing Milestones Will Eventually Support Stronger Long Term Earnings Visibility
Analysts have reduced their price target on PeptiDream to ¥1,600 from ¥2,700, citing slower than expected progress in product out-licensing as the main reason for the adjustment. Analyst Commentary Bullish Takeaways Bullish analysts still see value at the revised price target of ¥1,600, arguing that expectations now better reflect the current pace of out-licensing activity.4587: Out Licensing Progress Will Support Stronger Long Term Earnings Visibility
Analysts have lowered their price target on PeptiDream to ¥2,825 from ¥3,008, citing slightly reduced fair value assumptions following slower than expected product out licensing, as reflected in updated discount rate, revenue growth, profit margin, and future P/E inputs. Analyst Commentary Recent research points to a more cautious stance on PeptiDream, with rating and target price adjustments linked mainly to timing risks around product out licensing.
4587: Out Licensing Progress And 2026 Earnings Targets Will Drive Future Upside
Analysts have modestly raised their fair value estimate for PeptiDream to ¥4,400 from ¥4,255, citing updated assumptions around discount rate, revenue growth, profit margin, and forward P/E, even as some have turned more cautious with a lower Street price target of ¥1,600 reflecting slower than expected product out licensing. Analyst Commentary Recent Street commentary highlights a mix of caution on timing of product out licensing and incremental confidence in PeptiDream's long term potential, reflected in the modest lift in fair value estimates despite a lower Street price target concentrated around ¥1,600.4587: Oral Autoimmune Pipeline And siRNA Milestones Will Support Stronger Long Term Outlook
Analysts now set their PeptiDream price target at ¥3,008, down slightly from ¥3,033, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E. What's in the News PeptiDream issued consolidated earnings guidance for the fiscal year ending December 31, 2026, with expected revenue of ¥32,000 million, core operating profit and operating profit of ¥4,600 million, and profit attributable to owners of parent of ¥3,000 million (Corporate guidance).Recent updates
4587: Out Licensing Milestones Will Eventually Support Stronger Long Term Earnings Visibility
Analysts have reduced their price target on PeptiDream to ¥1,600 from ¥2,700, citing slower than expected progress in product out-licensing as the main reason for the adjustment. Analyst Commentary Bullish Takeaways Bullish analysts still see value at the revised price target of ¥1,600, arguing that expectations now better reflect the current pace of out-licensing activity.4587: Out Licensing Progress Will Support Stronger Long Term Earnings Visibility
Analysts have lowered their price target on PeptiDream to ¥2,825 from ¥3,008, citing slightly reduced fair value assumptions following slower than expected product out licensing, as reflected in updated discount rate, revenue growth, profit margin, and future P/E inputs. Analyst Commentary Recent research points to a more cautious stance on PeptiDream, with rating and target price adjustments linked mainly to timing risks around product out licensing.4587: Out Licensing Progress And 2026 Earnings Targets Will Drive Future Upside
Analysts have modestly raised their fair value estimate for PeptiDream to ¥4,400 from ¥4,255, citing updated assumptions around discount rate, revenue growth, profit margin, and forward P/E, even as some have turned more cautious with a lower Street price target of ¥1,600 reflecting slower than expected product out licensing. Analyst Commentary Recent Street commentary highlights a mix of caution on timing of product out licensing and incremental confidence in PeptiDream's long term potential, reflected in the modest lift in fair value estimates despite a lower Street price target concentrated around ¥1,600.4587: Oral Autoimmune Pipeline And siRNA Milestones Will Support Stronger Long Term Outlook
Analysts now set their PeptiDream price target at ¥3,008, down slightly from ¥3,033, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E. What's in the News PeptiDream issued consolidated earnings guidance for the fiscal year ending December 31, 2026, with expected revenue of ¥32,000 million, core operating profit and operating profit of ¥4,600 million, and profit attributable to owners of parent of ¥3,000 million (Corporate guidance).4587: Expanded Oral Pipeline And 2026 Milestones Will Drive Future Upside Potential
Analysts have slightly adjusted their price target on PeptiDream to ¥4,255 from ¥4,281 to reflect updated views on fair value, alongside refreshed assumptions for revenue growth, profit margin, discount rate and future P/E. What's in the News PeptiDream issued consolidated earnings guidance for the fiscal year ending December 31, 2026, expecting revenue of ¥32,000 million, core operating profit and operating profit of ¥4,600 million, and profit attributable to owners of parent of ¥3,000 million.Analysts Have Lowered Expectations For PeptiDream Inc. (TSE:4587) After Its Latest Results
Feb 18
4587: Oral Autoimmune Pipeline Progress Will Drive Stronger Long Term Outlook
Analysts have trimmed their price target on PeptiDream to reflect a fair value of ¥3,033, down from ¥3,271, as they factor in slightly softer revenue growth and profit margin assumptions, along with a modestly higher discount rate and P/E multiple outlook. What's in the News PeptiDream reported a revision to its fiscal year 2025 guidance, now expecting revenue of ¥18,000 million instead of ¥49,000 million, with an operating loss of ¥5,400 million and a loss attributable to owners of parent of ¥4,000 million, citing delays in anticipated milestones and partnering deals including its oral myostatin program.
4587: Milestone Progress In RNAi Delivery Platform Will Support Future Upside
Analysts now mark their fair value estimate for PeptiDream at ¥2,600, up from ¥2,500, reflecting adjustments to discount rates, revenue growth assumptions, profit margins, and a higher future P/E multiple. What's in the News PeptiDream reported a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals, supporting a modular platform for precision siRNA delivery using macrocyclic peptides to target organs beyond the liver, with associated milestone payments and potential future royalties from Alnylam products (Key Developments).4587: Expanded Pipeline Milestones Will Drive Future Upside Potential
Analysts have reduced their price expectations for PeptiDream, reflecting updated assumptions for slightly lower revenue growth and profit margins, along with a higher future P/E multiple. Together, these changes reduce the implied upside from prior targets on a discounted cash flow basis.4587: Rebound In Partnering Revenues Will Drive Strong Upside Potential
Analysts have trimmed their price target on PeptiDream from ¥4,830 to ¥4,281, reflecting a slightly higher discount rate, even as they modestly raise long term revenue growth and profit margin assumptions and apply a lower future P E multiple. What's in the News PeptiDream sharply cut its FY25 revenue guidance to JPY 18 billion from JPY 49 billion, and now expects an operating loss of JPY 5.4 billion instead of a JPY 21.6 billion profit, as milestone and partnering revenues shift into FY26 (company guidance).This Just In: Analysts Are Boosting Their PeptiDream Inc. (TSE:4587) Outlook for Next Year
Dec 044587: Radiopharmaceutical Pipeline Progress Will Drive Stronger Long Term Outlook
Analysts have modestly reduced their price target on PeptiDream from ¥3,414 to ¥3,271 as they incorporate a slightly higher discount rate, even as they update their assumptions to reflect stronger revenue growth, improved profitability, and a lower future P/E multiple. What's in the News PeptiDream, PDRadiopharma, and Curium have initiated a registrational Phase 2 clinical trial in Japan for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting PSMA expressed on prostate cancer cells (Key Developments).Is PeptiDream (TSE:4587) Using Too Much Debt?
Oct 05AI Discovery And Peptide Pipeline Will Expand Horizons
With both the discount rate and future P/E multiple showing only negligible movement, there has been no material change to PeptiDream's consensus analyst fair value, which remains steady at ¥3414. Valuation Changes Summary of Valuation Changes for PeptiDream The Consensus Analyst Price Target remained effectively unchanged, at ¥3414.PeptiDream (TSE:4587) Seems To Use Debt Rather Sparingly
Jun 23Here's Why We Think PeptiDream (TSE:4587) Might Deserve Your Attention Today
Apr 17
Advancements In Radiopharmaceutical Pipeline And Novartis Deal Will Drive Future Success
Expansion of deals and strategic partnerships positions PeptiDream for substantial future revenue growth from clinical advancements and imaging collaborations.PeptiDream (TSE:4587) Has A Rock Solid Balance Sheet
Mar 08Bullish: Analysts Just Made A Decent Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Feb 19Earnings Miss: PeptiDream Inc. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
Feb 17PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings
Feb 14Are Investors Undervaluing PeptiDream Inc. (TSE:4587) By 39%?
Dec 22PeptiDream's (TSE:4587) Performance Is Even Better Than Its Earnings Suggest
Nov 21PeptiDream Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now
Nov 18Is PeptiDream (TSE:4587) Using Too Much Debt?
Nov 15PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings
Oct 31Do PeptiDream's (TSE:4587) Earnings Warrant Your Attention?
Oct 15PeptiDream Inc. (TSE:4587) Shares Could Be 37% Below Their Intrinsic Value Estimate
Aug 29PeptiDream Inc. Just Beat Revenue Estimates By 13%
Aug 12PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Jun 30News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Jun 02PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues
Apr 30Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?
Apr 29PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors
Mar 03Rendimenti per gli azionisti
| 4587 | JP Biotechs | JP Mercato | |
|---|---|---|---|
| 7D | 0.8% | -4.4% | 0.2% |
| 1Y | -42.2% | -2.4% | 38.0% |
Ritorno vs Industria: 4587 ha avuto una performance inferiore rispetto al JP Biotechs che ha registrato un rendimento -2.4 % nell'ultimo anno.
Rendimento vs Mercato: 4587 ha avuto una performance inferiore al mercato JP che ha registrato un rendimento 38 % nell'ultimo anno.
Volatilità dei prezzi
| 4587 volatility | |
|---|---|
| 4587 Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in JP Market | 9.5% |
| 10% least volatile stocks in JP Market | 2.4% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di 4587 è stato volatile rispetto al mercato JP.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di 4587 è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni JP.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2006 | 645 | Patrick Crawford Reid | www.peptidream.com |
PeptiDream Inc. è un'azienda biofarmaceutica che si occupa della scoperta e dello sviluppo di peptidi vincolati, piccole molecole e farmaci peptidici coniugati. L'azienda sviluppa i suoi prodotti sulla base del suo Peptide Discovery Platform System, una piattaforma per la ricerca di farmaci che consente la produzione di librerie di peptidi non standard per l'identificazione di candidati peptidi macrociclici potenti e selettivi, che possono poi essere sviluppati in prodotti terapeutici e diagnostici a base di peptidi, piccole molecole, coniugati peptide-farmaco e coniugati peptide multifunzionali. La sua pipeline di sviluppo comprende PD-L1 indicato per l'oncologia e attualmente in fase di sviluppo clinico Ph1; PD-L1 BMS-986229 indicato per l'oncologia e attualmente in fase di sviluppo clinico Ph1; CD38 BHV-1100 + Cellule NK indicato per il mieloma multiplo e attualmente in fase di sviluppo clinico Ph1; S2-protein PA-001 indicato per COVID-19 e attualmente in fase di sviluppo clinico Ph1; GhR AZP-3813 indicato per l'acromegalia/NET e attualmente in fase di sviluppo clinico Ph1; Glypican-3 indicato per il cancro al fegato e attualmente in fase di sviluppo preclinico; Myostatin indicato per DMD/disturbi muscolari e attualmente in fase di sviluppo preclinico; TfR indicato per i disturbi neuromuscolari e attualmente in fase di sviluppo preclinico; c-Kit indicato per le condizioni allergiche e attualmente in fase di sviluppo preclinico; c-Met attualmente in fase di sviluppo preclinico; e HA-protein indicato per l'influenza e attualmente in fase di sviluppo preclinico.
PeptiDream Inc. Riepilogo dei fondamenti
| 4587 statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | JP¥150.79b |
| Utili (TTM) | -JP¥3.75b |
| Ricavi(TTM) | JP¥18.52b |
4587 è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| 4587 Conto economico (TTM) | |
|---|---|
| Ricavi | JP¥18.52b |
| Costo del fatturato | JP¥11.00b |
| Profitto lordo | JP¥7.52b |
| Altre spese | JP¥11.27b |
| Utili | -JP¥3.75b |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -29.01 |
| Margine lordo | 40.61% |
| Margine di profitto netto | -20.24% |
| Rapporto debito/patrimonio netto | 33.1% |
Come si è comportato 4587 nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/01 19:33 |
| Prezzo dell'azione a fine giornata | 2026/05/01 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
PeptiDream Inc. è coperta da 14 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Shan He | Bernstein |
| Hidemaru Yamaguchi | Citigroup Inc |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |